Live Breaking News & Updates on Stephaniet Le

Stay updated with breaking news from Stephaniet le. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Combined Rituximab + Omalizumab Promising for Refractory BP

Bullous pemphigoid has high morbidity and mortality, especially in people with comorbidities common to older adults, yet no Food and Drug Administration–approved therapies for BP exist. ....

United States , Stephaniet Le , University Of California , Drug Administration , Corticosteroids Are , Biologic Therapy , Antineoplastic Drug , Nti Cancer Agents , Monoclonal Antibody , Bullous Pemphigoid , Topical Corticosteroid , Elder Care , Geriatric Medicine , Older Adults , Senior Citizens , Elderly Concerns Of Older Adults ,

Rituximab, Omalizumab Combination Therapy Well-Tolerated for Patients With Bullous Pemphigoid

This data may bring patients with the rare immunobullous disease closer to an eventual FDA-approved treatment. ....

United States , Stephaniet Le , University Of California , Department Of Dermatology , Department Of Dermatology At University California , Pacific Islander , Bullous Pemphigoid ,

Rituximab, Omalizumab Combination Therapy Well-Tolerated for Bullous Pemphigoid Patients

This data may bring patients with the rare immunobullous disease closer to an eventual FDA-approved treatment.
....

United States , Stephaniet Le , Department Of Dermatology At University California , Department Of Dermatology , University Of California , Drug Administration , Pacific Islander , Hispanic White , Omalizumab Combination Therapy , Bullous Pemphigoid ,